Apolipoprotein AII Is a Regulator of Very Low Density Lipoprotein Metabolism and Insulin Resistance.

Apolipoprotein AII Is a Regulator of Very Low Density Lipoprotein Metabolism and Insulin Resistance. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Apolipoprotein AII Is a Regulator of Very Low Density Lipoprotein Metabolism and Insulin Resistance. Abstract Text:

Apolipoprotein AII (apoAII) transgenic (apoAIItg) mice exhibit several traits associated with the insulin resistance (IR) syndrome, including IR, obesity, and a marked hypertriglyceridemia. Because treatment of the apoAIItg mice with rosiglitazone ameliorated the IR and hypertriglyceridemia, we hypothesized that the hypertriglyceridemia was due largely to overproduction of very low density lipoprotein (VLDL) by the liver, a normal response to chronically elevated insulin and glucose. We now report in vivo and in vitro studies that indicate that hepatic fatty acid oxidation was reduced and lipogenesis increased, resulting in a 25% increase in triglyceride secretion in the apoAIItg mice. In addition, we observed that hydrolysis of triglycerides from both chylomicrons and VLDL was significantly reduced in the apoAIItg mice, further contributing to the hypertriglyceridemia. This is a direct, acute effect, because when mouse apoAII was injected into mice, plasma triglyceride concentrations were significantly increased within 4 h. VLDL from both control and apoAIItg mice contained significant amounts of apoAII, with approximately 4 times more apoAII on apoAIItg VLDL. ApoAII was shown to transfer spontaneously from high density lipoprotein (HDL) to VLDL in vitro, resulting in VLDL that was a poorer substrate for hydrolysis by lipoprotein lipase. These results indicate that one function of apoAII is to regulate the metabolism of triglyceride-rich lipoproteins, with HDL serving as a plasma reservoir of apoAII that is transferred to the triglyceride-rich lipoproteins in much the same way as VLDL and chylomicrons acquire most of their apoCs from HDL.

Apolipoprotein AII Is a Regulator of Very Low Density Lipoprotein Metabolism and Insulin Resistance. Publishing Authors By Initials

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Apolipoprotein AII Is a Regulator of Very Low Density Lipoprotein Metabolism and Insulin Resistance. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: The Journal of biological chemistry

VOLUME: 283

Page Numbers: 11633-44

Journal Abbreviation: J. Biol. Chem.

ISSN: 0021-9258

DAY: 26

MONTH: 12

YEAR: 2007

Apolipoprotein AII Is a Regulator of Very Low Density Lipoprotein Metabolism and Insulin Resistance. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 2985121

Apolipoprotein AII Is a Regulator of Very Low Density Lipoprotein Metabolism and Insulin Resistance. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Apolipoprotein AII Is a Regulator of Very Low Density Lipoprotein Metabolism and Insulin Resistance. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Apolipoprotein AII Is a Regulator of Very Low Density Lipoprotein Metabolism and Insulin Resistance.

AFFILIATION: Departments of Medicine/Cardiology University of California, Los Angeles, Los Angeles, California 90095.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: J Biol Chem

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Apolipoprotein AII Is a Regulator of Very Low Density Lipoprotein Metabolism and Insulin Resistance Related Publications

• A genome-wide set of congenic mouse strains derived from CAST/Ei on a C57BL/6 background.
• Apolipoprotein A-II: a protein in search of a function.
• Apolipoprotein AII Is a Regulator of Very Low Density Lipoprotein Metabolism and Insulin Resistance.
• Association of stearoyl-CoA desaturase 1 activity with familial combined hyperlipidemia.
• Granulocyte macrophage colony-stimulating factor regulates dendritic cell content of atherosclerotic lesions.
• High-resolution mapping of gene expression using association in an outbred mouse stock.
• Identification of Abcc6 as the major causal gene for dystrophic cardiac calcification in mice through integrative genomics.
• Identification of pathways for atherosclerosis in mice: integration of quantitative trait locus analysis and global gene expression data.
• Integrating genetic and gene expression data: application to cardiovascular and metabolic traits in mice.
• Integrating global gene expression analysis and genetics.
• Linkage between the APOB gene and serum ApoB levels in a large pedigree from the Bogalusa Heart Study.
• Localization of the mouse glucocorticoid receptor-interacting protein 1 gene (Grip1) to proximal chromosome 1 by linkage analysis.
• Mapping, genetic isolation, and characterization of genetic loci that determine resistance to atherosclerosis in C3H mice.
• Metabolic syndrome as a modifier of atherosclerosis in murine models.
• Network-centered view of coronary artery disease.
• Trypanosoma congolense: paraoxonase 1 prolongs survival of infected mice.